• Cellectar Biosciences will present new Phase 2b CLOVER WaM subgroup results at ASCO on June 1, 2026.
• The analysis showed strong, durable responses for iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia following BTK inhibitor therapy.
• Tolerability was described as manageable, with severe side effects limited to blood-count reductions.
• The data supported a plan to seek US accelerated approval, with a Phase 3 confirmatory trial targeted for 4Q26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.